Gender-Affirming Orchiectomy in Transgender Women with Prostate Cancer
The question conflates two distinct clinical scenarios: cisgender men with prostate cancer undergoing therapeutic castration versus transgender women who may undergo gender-affirming orchiectomy either before or after prostate cancer diagnosis.
Key Distinction: Therapeutic vs. Gender-Affirming Surgery
Cisgender men with prostate cancer do not pursue "sex change operations" after surgical castration for impotence. The evidence shows that while bilateral orchiectomy for prostate cancer treatment causes sexual dysfunction that 55% of previously sexually active patients find disturbing 1, this does not lead to gender transition. These patients experience body image concerns and sexual dysfunction, but their sex-role identity remains unchanged after the procedure 1.
Transgender Women and Prostate Cancer: The Actual Clinical Scenario
For transgender women, orchiectomy is performed as gender-affirming care, not as a response to cancer-related impotence. The clinical reality is fundamentally different:
When Orchiectomy Precedes Cancer Diagnosis
- Transgender women who undergo gender-affirming orchiectomy do so to align their physical characteristics with their gender identity, typically as part of feminizing hormone therapy 2
- This procedure eliminates the need for gonadotropin-releasing hormone agonists or antagonists if prostate cancer develops later 2
- Prostate cancer incidence in this population is extremely low (0.04% overall, 0.13% for those starting hormones after age 40) 3
- The procedure provides significant benefits including reduction in gender dysphoria, decreased hormone therapy requirements, and improved quality of life 4
When Cancer Occurs in Transgender Women
A transgender woman with prostate cancer may choose orchiectomy over medical castration specifically because residual testes exacerbate gender dysphoria 2. This is not a "sex change operation due to impotence" but rather selecting the surgical castration option that better aligns with their existing gender identity 2.
Clinical Implications
The 2025 MASCC guidelines emphasize that treatment decisions for transgender patients with hormone-sensitive cancers must account for:
- Anatomy inventory: Clinicians must document which organs remain after any gender-affirming procedures 2
- Gender dysphoria considerations: Some transgender women may prefer orchiectomy over medical androgen deprivation because it addresses both cancer treatment and gender-affirming goals simultaneously 2
- Quality of life: Gender-affirming therapy remains life-saving for many transgender individuals, improving depression, anxiety, and suicidality 2
Important Caveat
Cisgender individuals undergoing cancer treatments like orchiectomy may experience what is labeled as body image disturbance or distress, but this is fundamentally different from gender dysphoria 2. The 55% of cisgender men who find sexual dysfunction after therapeutic orchiectomy disturbing 1 are not candidates for gender transition—they are experiencing treatment side effects within their existing gender identity.
Bottom Line
The premise of the question is incorrect. Cisgender prostate cancer patients do not pursue gender transition after castration. However, transgender women with prostate cancer may appropriately choose surgical over medical castration when it serves dual purposes: cancer treatment and gender affirmation 2.